Jonson & Johnson and AstraZeneca resumed trials of their experimental coronavirus vaccine after approval by regulators, local media said on Friday.
ASTRAZENECA’S TRIALS HAD BEEN PAUSED AFTER NEUROLOGICAL ILLNESS FOUND IN A PARTICIPANT
The US Food and Drug Administration (FDA) gave the green light to both companies to continue their vaccine trials.
The FDA examined the diseases on subjects, which led the studies to pause, and decided that the diseases did not stem from the coronavirus vaccines.
“The restart of clinical trials across the world is great news as it allows us to continue our efforts to develop this vaccine to help defeat this terrible pandemic,” said Pascal Soriot, the chief executive officer of AstraZeneca.
On Sept. 6, AstraZeneca’s US trials were paused after a serious neurological illness found in a participant. On Oct. 12, Johnson & Johnson paused its trials after a study participant became ill.
